{
    "2019-01-08": [
        [
            {
                "time": "2018-01-08",
                "original_text": "格隆汇港股聚焦(1.8)︱长城汽车12月销量升6.54% 全年销量达105.3万辆",
                "features": {
                    "keywords": [
                        "长城汽车",
                        "销量",
                        "增长",
                        "12月",
                        "全年"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "汽车"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "8日晚公告精选：金财互联更名去除“权健”字样",
                "features": {
                    "keywords": [
                        "金财互联",
                        "更名",
                        "权健"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "互联网",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "复星医药旗下四价流感疫苗临床试验申请获批",
                "features": {
                    "keywords": [
                        "复星医药",
                        "四价流感疫苗",
                        "临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "6亿！复星医药转让达芬奇手术机器人独家代理权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "达芬奇手术机器人",
                        "转让",
                        "独家代理权"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "1月8日上市公司晚间公告速递",
                "features": {
                    "keywords": [
                        "上市公司",
                        "公告",
                        "速递"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "复星医药：子公司获四价流感病毒裂解疫苗临床试验批准",
                "features": {
                    "keywords": [
                        "复星医药",
                        "子公司",
                        "四价流感病毒裂解疫苗",
                        "临床试验",
                        "批准"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "医药生物行业月报:结构调整下多数公司进入价值区间 创新是最确定的方向",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业月报",
                        "结构调整",
                        "价值区间",
                        "创新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}